ALS is a disease which affects the motor neurons in the brain and spinal cord leading muscle weakness and death, generally 3-5 years after an initial diagnosis. Zhittya Genesis Medicine plans to file an IND with the US FDA for the treatment of ALS after completion of its animal studies. Zhittya believes that its drug treatment for ALS is a disease modifying agent addressing the root cause of ALS, namely a lack of blood flow to selected motor neurons in the brain.

This is video explains our in-depth theory behind treating ALS with FGF-1.